



**pan-Canadian Oncology Drug Review
Patient Advocacy Group Feedback on a pCODR
Expert Review Committee Initial
Recommendation**

**Ibrutinib (Imbruvica) for Chronic Lymphocytic
Leukemia/Small Cell Lymphoma**

**CLL Patient Advocacy Group (CLLPAG) and The
Leukemia & Lymphoma Society of Canada (LLSC)**

March 5, 2015

Feedback on pERC Initial Recommendation

Name of the drug indication(s): Ibrutinib (Imbruvica) for CLL and SLL
 Name of registered patient advocacy group: The Leukemia and Lymphoma Society of Canada & CLL Patient Advocacy Group

**pCODR may contact this person if comments require clarification. Contact information will not be included in any public posting of this document by pCODR.*

1.1 Comments on the Initial Recommendation

a) Please indicate if the patient advocacy group agrees or disagrees with the initial recommendation:

agrees agrees in part disagree

LLSC and CLL PAG appreciate that the patient group submissions were taken into consideration and recognized as well structured and organized. CLL/SLL patients need new drugs that demonstrate a survival benefit and the ability to take medication orally will dramatically improve the quality of life for patients. As longer follow-up data becomes available, the clinical benefits will hopefully become more apparent. Patients understand that every drug has side effects and are willing to manage the toxicities associated with ibrutinib. We understand the concerns regarding cost of the drug especially because this drug is intended for long term use. We hope that the cost of ibrutinib can be made affordable to allow patients who would benefit from this drug to have access. The Initial Recommendation Document and its components are clearly worded and the intent and reasons are easy to understand.

b) Notwithstanding the feedback provided in part a) above, please indicate if the patient advocacy group would support this initial recommendation proceeding to final pERC recommendation ("early conversion"), which would occur within 2(two) business days of the end of the consultation period.

Support conversion to final recommendation. Do not support conversion to final recommendation.
 Recommendation does not require reconsideration by pERC. Recommendation should be reconsidered by pERC.

c) Please provide feedback on the initial recommendation

Page Number	Section Title	Paragraph, Line Number	Comments and Suggested Changes to Improve Clarity
			No comments

1.2 Comments Related to Patient Advocacy Group Input

Page Number	Section Title	Paragraph, Line Number	Comments related to initial patient advocacy group input
			No comments

1.3 Additional Comments About the Initial Recommendation Document

Page Number	Section Title	Paragraph, Line Number	Additional Comments
7	Patient based values	4 th paragraph, line 7/8	low red blood counts should be high white blood counts